



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

Applicant(s): Bevyn Jarrott, et al.

Examiner: Unassigned

Serial No.: 09/743,379

Art Unit: Unassigned

Filed: January 8, 2001

Docket: 14099

For: PHARMACEUTICAL
AGENTS

Dated: April 20, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §§1.56, 1.97 AND 1.98

Sir:

Applicants, in order to meet their duty of disclosure, set forth at 37 C.F.R. §1.56, submit herewith those references which they deem relevant to the claims of the present application.

The relevant references are as follows:

1. U.S. Patent No. 3,274,190 to Gray et al.
2. WO A 93/10116 to Pfizer Inc.
3. Chemical Abstracts 69:77243 T. Tsuji et al., "Synthesis of 2-substituted – 4, 6- diamino-s-triazines"

It is noted all of the cited patent publications and journal references are in the English language.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington DC 20231 on April 20, 2001.

Dated: April 20, 2001


Michelle Mustafa


BEST AVAILABLE COPY

Applicants respectfully request that the above-mentioned references be made of record in the file of the present application. To that end, applicants submit herewith the aforementioned references and the completed Form PTO-1449, setting forth these references.

Applicants submit that the filing of this Information Disclosure Statement is being submitted before the issuance of an office action on the merits of the subject application. Therefore, no Declaration or fee is required to effect the filing of this Information Disclosure Statement.

Consideration of this Information Disclosure Statement is respectfully requested, since the information provided herein may be material to the patentability of the subject application as defined in 37 C.F.R. §1.56.

Respectfully submitted,


Edward W. Grolz
Registration No. 33,705

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

EWG:yp

BEST AVAILABLE COPY

PCT

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))Docket No.
14099

Re Application Of: Bevyn Jarrott, et al.

Serial No.

09/43,379

Filing Date

January 8, 2001

Examiner

Unassigned

Group Art Unit

Unassigned

Title: **PHARMACEUTICAL AGENTS**

Address to:

Assistant Commissioner for Patents
Washington, D.C. 20231**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

BEST AVAILABLE COPY

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
14099

In Re Application Of: **Bevyn Jarrott, et al.**

Serial No.
43,379

Filing Date
January 8, 2001

Examiner
Unassigned

Group Art Unit
Unassigned

Title: **PHARMACEUTICAL AGENTS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____) on _____ (Date) _____ Signature _____
Typed or Printed Name of Person Signing Certificate _____

*This certificate may only be used if paying by deposit account.

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on April 20, 2001 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231. _____ Signature of Person Mailing Correspondence _____
Mishelle Mustafa
Typed or Printed Name of Person Mailing Correspondence _____

Dated: April 20, 2001

Edward W. Grolz
Registration No. 33,705

SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
EWG:yp

BEST AVAILABLE COPY

CC: